Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab

Academic Article


  • Our purpose was to study the safety, distribution, pharmacokinetics, immunogenicity, and tumor response of intraperitoneal 212Pb-TCMCtrastuzumab (TCMC is S-2-(4-isothiocyanatobenzyl)-1,4,7,10- tetraaza-1,4,7,10-tetra(2-carbamoylmethyl)cyclododecane) in patients with human epidermal growth factor receptor type 2 (HER-2)- expressing malignancy.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Meredith R; Torgue J; Shen S; Fisher DR; Banaga E; Bunch P; Morgan D; Fan J; Straughn JM
  • Start Page

  • 1636
  • End Page

  • 1642
  • Volume

  • 55
  • Issue

  • 10